London open: FTSE takes cues from Wall Street 'Santa rally'
27th Dec 2023 08:26
(Sharecast News) - London's stocks returned from the Christmas break in the green on Wednesday, boosted by a late Santa rally on Wall Street overnight.
Read moreAstraZeneca to buy Gracell Technologies for $1.2bn
27th Dec 2023 07:02
(Sharecast News) - AstraZeneca on Wednesday said it was buying Gracell Biotechnologies, a global clinical-stage biopharmaceutical company developing cell therapies for the treatment of cancer and autoimmune diseases, for $1.2bn.
Read moreAstraZeneca gets FDA green light for nerve disease treatment
22nd Dec 2023 07:17
(Sharecast News) - The US Food and Drug Administration has approved the Wainua nerve disease treatment jointly developed by AstraZeneca and Ionis Pharmaceuticals.
Read moreLondon close: Stocks slip as investors digest US inflation
12th Dec 2023 16:00
(Sharecast News) - London's markets finished in the red on Tuesday, as investors digested a slight decrease in consumer inflation in the US, while the UK's unemployment figures remained stable.
Read moreLondon midday: FTSE still firmer ahead of US inflation print
12th Dec 2023 12:07
(Sharecast News) - London's markets remained relatively stable by midday on Tuesday, with the top-flight index still in the green after fresh jobs data showed a slowdown in wage growth.
Read moreAstraZeneca to buy US vaccine maker Icosavax for up to $1.1bn
12th Dec 2023 07:16
(Sharecast News) - AstraZeneca said on Tuesday that it has agreed to buy Icosavax - a US-based clinical-stage biopharmaceutical company - for up to $1.1bn.
Read moreAstraZeneca calls off two phase III trials into hyperkalaemia treatment
1st Dec 2023 08:01
(Sharecast News) - Drugmaker AstraZeneca has called off two phase III trials on its hyperkalaemia treatment after a series of logistical challenges.
Read moreLondon close: Stocks start week in subdued state
27th Nov 2023 16:12
(Sharecast News) - London's financial markets saw a somewhat subdued performance on Monday, as concerns regarding the Chinese economy cast a shadow over investor sentiment.
Read moreLondon close: Stocks higher despite weaker retail sales data
17th Nov 2023 15:20
(Sharecast News) - London's stock markets finished in a positive state on Friday despite weaker-than-expected UK retail sales figures.
Read moreAstraZeneca gets US approval for breast cancer treatment
17th Nov 2023 07:16
(Sharecast News) - AstraZeneca's 'Truqap', or capivasertib, in combination with 'Faslodex', or fulvestrant, has secured approval from the US Food and Drug Administration (FDA) for specific breast cancer treatments, the company announced on Friday.
Read moreAstraZeneca's latest lung cancer trial fails its primary endpoint
14th Nov 2023 09:22
(Sharecast News) - AstraZeneca announced on Tuesday that its 'PACIFIC-2' phase three trial for Imfinzi, or durvalumab, concurrently administered with chemoradiotherapy (CRT), did not achieve its primary endpoint of progression-free survival compared to CRT alone.
Read moreLondon close: Stocks gain as investors await Powell speech
9th Nov 2023 15:02
(Sharecast News) - London's stock markets were buoyant at the close of trading on Thursday, influenced by Chinese inflation data, a substantial influx of corporate news, and a speech from the Fed chair later in the global day.
Read moreAstraZeneca hikes guidance after strong third quarter
9th Nov 2023 07:18
(Sharecast News) - AstraZeneca released its financial results for the third quarter and first nine months of 2023 on Thursday, hiking its full-year guidance on the back of a robust performance and momentum in several segments.
Read moreAstraZeneca invests $220m in French gene-editing group Cellectis
1st Nov 2023 07:33
(Sharecast News) - AstraZeneca is to invest in French biopharma group Cellectis to use its gene-editing technologies to develop next-gen therapeutics in areas like oncology, immunology and rare diseases.
Read moreAstraZeneca agrees to settle most Nexium, Prilosec claims
3rd Oct 2023 07:24
(Sharecast News) - Global pharmaceutical company AstraZeneca has agreed to settle litigation on product liability related to two of its widely-used heartburn drugs, Nexium and Prilosec, it announced on Tuesday.
Read more